 | Up a level |
König, D; Schär, S; Vuong, D; Guckenberger, M; Furrer, K; Opitz, I; Weder, W; Rothschild, S I; Ochsenbein, A; Zippelius, A; Addeo, A; Mark, M; Eboulet, E I; Hayoz, S; Thierstein, S; Betticher, D C; Ris, H-B; Stupp, R; Curioni-Fontecedro, A; Peters, S; ... (2022). Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]. ESMO open, 7(3), p. 100494. Elsevier 10.1016/j.esmoop.2022.100494
König, D; Schär, S; Vuong, D; Guckenberger, M; Furrer, K; Opitz, I; Weder, W; Rothschild, S I; Ochsenbein, A; Zippelius, A; Addeo, A; Mark, M; Eboulet, E I; Hayoz, S; Thierstein, S; Betticher, D C; Ris, H-B; Stupp, R; Curioni-Fontecedro, A; Peters, S; ... (2022). Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials. ESMO open, 7(2), p. 100455. Elsevier 10.1016/j.esmoop.2022.100455
Koelzer, V H; Herzig, P; Zlobec, Inti; Heinzelmann, V; Lardinois, D; Walseng, E; Rader, C; Mertz, K D; Zippelius, A; Thommen, D S (2021). Integrated functional and spatial profiling of tumour immune responses induced by immunotherapy: the iPROFILER platform. Immuno-oncology technology, 10(C) Elsevier 10.1016/j.iotech.2021.100034
Rothschild, S; Amrein, Michael; Riether, Carsten; Gautschi, O; Schuster, N; Li, Q; Savic, S; Schneider, M; Biaggi, C; Bubendorf, L; Brutsche, M; Zippelius, A; Zander, T; Betticher, D; Früh, M; Stahel, R; Cathomas, R; Rauch, Daniel; Pless, M; Ochsenbein, Adrian; ... (October 2017). CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09). Journal of thoracic oncology, 12(11S2), S1864-S1865. Elsevier
Koelzer, V H; Glatz, K; Bubendorf, L; Weber, A; Gaspert, A; Cathomas, G; Lugli, Alessandro; Zippelius, A; Kempf, W; Mertz, K D (2017). [The pathology of adverse events with immune checkpoint inhibitors]. Der Pathologe, 38(3), pp. 197-208. Springer 10.1007/s00292-017-0281-1
